Search by Drug Name or NDC
NDC 25021-0668-05 Cisatracurium Besylate 2 mg/mL Details
Cisatracurium Besylate 2 mg/mL
Cisatracurium Besylate is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sagent Pharmaceuticals. The primary component is CISATRACURIUM BESYLATE.
Product Information
| NDC | 25021-0668 |
|---|---|
| Product ID | 25021-668_469efca1-43dc-4508-a260-fc969f20d620 |
| Associated GPIs | 74200013102014 |
| GCN Sequence Number | 024614 |
| GCN Sequence Number Description | cisatracurium besylate VIAL 2 MG/ML INTRAVEN |
| HIC3 | S7A |
| HIC3 Description | NEUROMUSCULAR BLOCKING AGENTS |
| GCN | 32771 |
| HICL Sequence Number | 010278 |
| HICL Sequence Number Description | CISATRACURIUM BESYLATE |
| Brand/Generic | Generic |
| Proprietary Name | Cisatracurium Besylate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | cisatracurium besylate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | mg/mL |
| Substance Name | CISATRACURIUM BESYLATE |
| Labeler Name | Sagent Pharmaceuticals |
| Pharmaceutical Class | Neuromuscular Nondepolarizing Blockade [PE], Nondepolarizing Neuromuscular Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA201836 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 25021-0668-05 (25021066805)
| NDC Package Code | 25021-668-05 |
|---|---|
| Billing NDC | 25021066805 |
| Package | 10 VIAL in 1 CARTON (25021-668-05) / 5 mL in 1 VIAL |
| Marketing Start Date | 2021-11-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |